Sutro Financial Statements From 2010 to 2025

STRO Stock  USD 0.88  0.10  12.82%   
Sutro Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sutro Biopharma's valuation are provided below:
Sutro Biopharma does not presently have any fundamental trend indicators for analysis.
Check Sutro Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sutro Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sutro financial statements analysis is a perfect complement when working with Sutro Biopharma Valuation or Volatility modules.
Check out the analysis of Sutro Biopharma Correlation against competitors.
To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.

Sutro Biopharma Company Return On Equity Analysis

Sutro Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Sutro Biopharma Return On Equity

    
  -3.48  
Most of Sutro Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sutro Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Sutro Biopharma has a Return On Equity of -3.4764. This is 85.5% lower than that of the Biotechnology sector and 90.47% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Sutro Biopharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Sutro Biopharma's current stock value. Our valuation model uses many indicators to compare Sutro Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sutro Biopharma competition to find correlations between indicators driving Sutro Biopharma's intrinsic value. More Info.
Sutro Biopharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sutro Biopharma's earnings, one of the primary drivers of an investment's value.

About Sutro Biopharma Financial Statements

Sutro Biopharma investors utilize fundamental indicators, such as revenue or net income, to predict how Sutro Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. Sutro Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.

Pair Trading with Sutro Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Sutro Stock

  0.63CVS CVS Health Corp Aggressive PushPairCorr
  0.41MRK Merck Company Aggressive PushPairCorr
  0.4XBIO Xenetic BiosciencesPairCorr
  0.38AVXL Anavex Life SciencesPairCorr
  0.37SLS Sellas Life SciencesPairCorr
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Sutro Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sutro Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sutro Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sutro Biopharma Stock:
Check out the analysis of Sutro Biopharma Correlation against competitors.
To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.